alexa Hepatitis B vaccination status among healthcare workers in a tertiary care hospital in Tripoli, Libya.
Immunology

Immunology

Journal of Vaccines & Vaccination

Author(s): Ziglam H, ElHattab M, Shingheer N, Zorgani A, Elahmer O

Abstract Share this page

Abstract BACKGROUND: The prevalence of hepatitis B virus (HBV) among healthcare workers (HCWs) in hospitals in developing countries is high. However, the vaccination status of these workers and its relationship with occupational factors are not well documented. AIM: The aim of this study was to evaluate the susceptibility of HCWs to HBV infection in the representative Tripoli Central Hospital in Libya and prepare a practical guideline to protect HCWs from occupational exposure. METHOD: In this cross-sectional study, a questionnaire survey was administered to 2705 healthcare workers of a university hospital in Tripoli. The questionnaire included vaccination status. Compliance with preventive practices against HBV infection was also assessed. RESULT: The overall vaccination coverage (anti-HBs) was 78.1\%. Furthermore, 82.6\% of HCWs had received at least one dose of vaccine, but only 72\% reported that they were fully vaccinated. The prevalence of hepatitis B surface antigen was 1.1\%. The mean prevalence of hepatitis B core antibody (anti-HBc) was 17.3\%. CONCLUSION: HCWs at hospitals are frequently exposed to blood-borne infections. Vaccines should be more readily available for Libyan HCWs, and current vaccination programs should be enforced. Copyright © 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved. This article was published in J Infect Public Health and referenced in Journal of Vaccines & Vaccination

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ivana Stojanovic
    New protocol for the generation of insulin-specific T regulatory cells
    PPT Version | PDF Version
  • Jessy S Deshane
    Longitudinal changes in airway microbiome signatures and immunoregulatory cell dynamics following Bronchial Thermoplasty
    PPT Version | PDF Version
  • Luis Gosalbez
    Key regulatory issues in the development of pharmabiotics in Europe
    PPT Version | PDF Version
  • Brian Littlechild
    The management of violence and aggression against staff in mental health work: responding effectively through a co-production approach to issues for service users, carers, staff and agencies
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Kazuo Yano
    Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
    PPT Version | PDF Version
  • Pierre Moine
    Systemic Antimicrobial Prophylaxis Issues
    PPT Version | PDF Version
  • Jan O Gordeladze
    Key regulatory junctions stabilizing the osteoblast phenotype: Implications for cell and tissue engineering
    PPT Version | PDF Version
  • Jane E Clougherty
    Issues of air pollution exposure science and epidemiology
    PPT Version | PDF Version
  • Dean A
    Identifying physical and psycho-social issues facing breast cancer survivors after definitive treatment for early breast cancer: a nurse-led clinic model
    PPT Version | PDF Version
  • Shulamith Kreitler
    Where, when and how to die: Insights into issues of critical nursing in cancer
    PPT Version | PDF Version
  • Magali Cordaillat-Simmons
    Pharmabiotics: A regulatory hurdle in Europe
    PPT Version | PDF Version
  • P V S Kishore
    Controversies and ethics of animal testing: Emerging issues and new challenges
    PPT Version | PDF Version
  • Aysegul TANIK
    Towards Effective Public Participation in Water Resources Management: Issues and Approaches in Turkey
    PPT Version | PDF Version
  • William Lee
    Regulatory roadmap for initiating a cell therapy drug into clinical trials in the US
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords